Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline ...

Pfizer (NYSE: PFE) has been southbound for the past three years. Following its success in the coronavirus market, which made it the first company in the biopharma industry to generate $100 billion in ...

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.

After the lofty dividend yield, the next big reason to buy Pfizer is its proven ability to survive in the highly competitive pharmaceutical sector. Not only is it a giant in the industry, with a $135 ...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

At $25.60, Pfizer (NYSE:PFE | PFE Price Prediction) sits in Hold territory on Wall Street’s consensus. The headline 6.7% ...

When it comes to pharmaceutical stocks, Pfizer probably isn't a screaming buy in 2026. But I also don't think it looks like a ...

Pfizer Inc. (NYSE:PFE) is one of the 7 Best Longevity Stocks to Buy Now. On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut ...